Nasus Pharma (NYSE: NSRX) Reports Positive Phase 2 NS002 Study Results

March 19, 2026

Market Overview Nasus Pharma (NYSE: NSRX) recently shared encouraging developments in its clinical programs, reflecting positively on investor sentiment. The company’s stock has attracted attention as it progresses through crucial stages of drug development. Market participants are closely watching the trajectory of NSRX stock amid ongoing advancements in treatments for allergic reactions. The latest updates from Nasus Pharma (NYSE: NSRX) amplify this focus, with progress indicating potential for substantial clinical…

Read More >>